Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
I give below details of changes in the Directors' interests in the Ordinary Shares and American Depositary Shares (ADSs) of GlaxoSmithKline plc.
On 30 June 2014, the Company's Non-Executive Directors were allocated notional Ordinary Shares at a price of £15.67 per Ordinary Share, and notional ADSs at a price of $53.64 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 April 2014 to 30 June 2014:
Non Executive Director |
Ordinary Shares |
American Depositary Shares (ADSs) |
|
|
|
Sir Christopher Gent |
3,988.513 |
|
|
|
|
Professor Sir Roy Anderson |
578.334 |
|
|
|
|
Dr Stephanie Burns |
|
433.930 |
|
|
|
Stacey Cartwright |
458.679 |
|
|
|
|
Lynn Elsenhans |
|
577.315 |
|
|
|
Judy Lewent |
|
367.897 |
|
|
|
Sir Deryck Maughan |
|
1,094.258 |
|
|
|
Dr Daniel Podolsky |
|
820.694 |
|
|
|
Tom de Swaan |
538.449 |
|
|
|
|
Jing Ulrich |
|
273.565 |
|
|
|
Hans Wijers |
458.679 |
|
|
|
|
|
|
|
The Company and the Non-Executive Directors were informed of these allocations on 1 July 2014.
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
V A Whyte
Company Secretary
2 July 2014